Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Friedman

Showing results (1411-1420 of 1,475) with videos related to

Pageof 148
Sort By:
Neurosurgical Focus|December 16, 2006
Phase II study of carboplatin (CBDCA) in progressive low-grade gliomasA Moghrabi, H S Friedman, D M Ashley, et al.
Cancer Cell|January 15, 2016
MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1BJing Hu, Tao Sun, Hui Wang, et al.
Neuro-Oncology|December 15, 2010
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaJohn H Sampson, Kenneth D Aldape, Gary E Archer, et al.
The Lancet. Child & Adolescent Health|April 2, 2023
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trialEric M Thompson, Daniel Landi, Michael C Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Phase II trial of temozolomide in patients with progressive low-grade gliomaJennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Parkinsonism & Related Disorders|December 17, 2010
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelinesMichael J Aminoff, Chad W Christine, Joseph H Friedman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II studyGamal Akabani, David A Reardon, R Edward Coleman, et al.
Neuro-Oncology|May 12, 2004
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant gliomaJennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.
British Journal of Cancer|August 17, 2000
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseW K Yung, R E Albright, J Olson, et al.
Pageof 148

Showing results (1411-1420 of 1,475) with videos related to

Sort By:
Pageof 148
Neurosurgical Focus|December 16, 2006
Phase II study of carboplatin (CBDCA) in progressive low-grade gliomasA Moghrabi, H S Friedman, D M Ashley, et al.
Cancer Cell|January 15, 2016
MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1BJing Hu, Tao Sun, Hui Wang, et al.
Neuro-Oncology|December 15, 2010
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaJohn H Sampson, Kenneth D Aldape, Gary E Archer, et al.
The Lancet. Child & Adolescent Health|April 2, 2023
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trialEric M Thompson, Daniel Landi, Michael C Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Phase II trial of temozolomide in patients with progressive low-grade gliomaJennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Parkinsonism & Related Disorders|December 17, 2010
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelinesMichael J Aminoff, Chad W Christine, Joseph H Friedman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II studyGamal Akabani, David A Reardon, R Edward Coleman, et al.
Neuro-Oncology|May 12, 2004
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant gliomaJennifer A Quinn, David A Reardon, Allan H Friedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasI Cokgor, G Akabani, C T Kuan, et al.
British Journal of Cancer|August 17, 2000
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseW K Yung, R E Albright, J Olson, et al.
Pageof 148